Ertugliflozin shows significant A1C reductions in type 2 diabetes
Merck and Pfizer have announced that two Phase III studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints.
Click on this link for more information.
